Madrigal pharmaceuticals provides clinical and business updates and reports 2022 second quarter financial results

Conshohocken, pa., aug. 04, 2022 (globe newswire) -- madrigal pharmaceuticals, inc. (nasdaq:mdgl), a clinical-stage biopharmaceutical company pursuing novel therapeutics for nonalcoholic steatohepatitis (nash), today provides a summary of recent corporate accomplishments and reports its second quarter 2022 financial results.
MDGL Ratings Summary
MDGL Quant Ranking